This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Paul Schaffer, Ph.D.
Associate Laboratory Director, Life Sciences at TRIUMF


Paul Schaffer completed his undergraduate in Chemistry and Biochemistry at the University of BC in 1998, followed by his graduate work in Chemistry at McMaster University in 2003. After 3 years as a Research Associate at the McMaster Nuclear Reactor, he joined GE Global Research in upstate New York as a Lead Scientist working on radiopharmaceutical development. He has been Associate Laboratory Director, Life Sciences at TRIUMF since 2012, and holds cross appointments in the Depts. of Chemistry at SFU and Radiology at UBC and is an affiliated scientist with the Research Centre for Nuclear Physics in Osaka, Japan.

In response to the 2007-2009 Tc-99m supply crises, Paul spearheaded one of three successive efforts along with his collaborators, to establish proof of concept commercial-scale production of Tc-99m. In recognition of his leadership, Schaffer was recognized by Business in Vancouver as one of British Columbia’s Top Forty under 40 individuals in 2013; followed by the collaborative team being awarded the NSERC Brockhouse Prize for Interdisciplinary Research in 2015. The technology was also the recipient of the 2017 World Council on Isotopes President’s Award, and the 2017 BC TECH - Most Promising Pre-Commercial Technology Award. After attracting over $19M in venture funding, he is now consulting as Chief Technology Officer of ARTMS, Inc. – a spinoff company formed based around the isotope supply technology developed.

His research efforts at TRIUMF remain focused on the production and chemical transformation of known and novel isotopes for imaging and therapy. His research interests include the development of novel radiofluorinated amino acids, as well as novel metal-chelate and radiolabeled large molecular weight targeting agents for various imaging and therapeutic applications. He has over 100 peer reviewed publications and 150 presentations, many invited and on the international stage.

Schaffer continues to re-define the TRIUMF Life’s Sciences program by focusing on its core competencies of accelerator beam applications, isotope production and radiopharmaceutical development, to deliver high-impact science.

Agenda Sessions

  • Emerging Trends in Targeted Therapies Utilizing Particle-Emitting Radiopharmaceuticals


Speakers at this event